Bioventus Net Worth
Bioventus Net Worth Breakdown | BVS |
Bioventus Net Worth Analysis
Bioventus' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Bioventus' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Bioventus' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Bioventus' net worth analysis. One common approach is to calculate Bioventus' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Bioventus' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Bioventus' net worth. This approach calculates the present value of Bioventus' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Bioventus' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Bioventus' net worth. This involves comparing Bioventus' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Bioventus' net worth relative to its peers.
Enterprise Value |
|
To determine if Bioventus is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bioventus' net worth research are outlined below:
| Bioventus had very high historical volatility over the last 90 days | |
| Bioventus has high likelihood to experience some financial distress in the next 2 years | |
| Bioventus has 394.85 M in debt with debt to equity (D/E) ratio of 1.17, which is OK given its current industry classification. Bioventus has a current ratio of 0.92, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Bioventus to invest in growth at high rates of return. | |
| The entity reported the last year's revenue of 512.35 M. Reported Net Loss for the year was (96.74 M) with profit before taxes, overhead, and interest of 302.71 M. | |
| About 70.0% of Bioventus shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Discretionary transaction by Juniper Investment Company, Llc of tradable shares of Bioventus subject to Rule 16b-3 |
Bioventus Quarterly Good Will |
|
Bioventus uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bioventus. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bioventus' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Bioventus' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bioventus is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bioventus backward and forwards among themselves. Bioventus' institutional investor refers to the entity that pools money to purchase Bioventus' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | American Century Companies Inc | 2024-09-30 | 638 K | Ophir Asset Management Pty Ltd | 2024-09-30 | 524.2 K | Oberweis Asset Management Inc | 2024-09-30 | 510.9 K | Millennium Management Llc | 2024-09-30 | 431.6 K | Charles Schwab Investment Management Inc | 2024-09-30 | 390.2 K | Renaissance Technologies Corp | 2024-09-30 | 387.9 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 380.8 K | Segall Bryant & Hamill | 2024-09-30 | 377.8 K | Aqr Capital Management Llc | 2024-09-30 | 366.7 K | Essex Woodlands Health Ventures | 2024-09-30 | 13 M | Juniper Investment Co, Llc | 2024-09-30 | 6.9 M |
Follow Bioventus' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 803.37 M.Market Cap |
|
Project Bioventus' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.46) | |
| Return On Capital Employed | (0.13) | (0.12) | |
| Return On Assets | (0.19) | (0.18) | |
| Return On Equity | (0.90) | (0.85) |
When accessing Bioventus' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Bioventus' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bioventus' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Bioventus' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bioventus. Check Bioventus' Beneish M Score to see the likelihood of Bioventus' management manipulating its earnings.
Evaluate Bioventus' management efficiency
Bioventus has Return on Asset of 0.0248 % which means that on every $100 spent on assets, it made $0.0248 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2476) %, meaning that it generated no profit with money invested by stockholders. Bioventus' management efficiency ratios could be used to measure how well Bioventus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.46 in 2024. Return On Capital Employed is likely to gain to -0.12 in 2024. At this time, Bioventus' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 3.3 M in 2024, whereas Other Current Assets are likely to drop slightly above 13.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.53 | 3.24 | |
| Tangible Book Value Per Share | (4.29) | (4.50) | |
| Enterprise Value Over EBITDA | (29.82) | (28.33) | |
| Price Book Value Ratio | 1.90 | 1.81 | |
| Enterprise Value Multiple | (29.82) | (28.33) | |
| Price Fair Value | 1.90 | 1.81 | |
| Enterprise Value | 688 M | 1.2 B |
The leadership approach at Bioventus' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Enterprise Value Revenue 2.0608 | Revenue 555.1 M | Quarterly Revenue Growth 0.15 | Revenue Per Share 8.679 | Return On Equity (0.25) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bioventus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bioventus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bioventus insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bioventus Corporate Filings
| 14th of November 2024 Other Reports | ViewVerify | |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 4th of November 2024 Other Reports | ViewVerify |
Bioventus Earnings per Share Projection vs Actual
Bioventus Corporate Management
| Anthony JD | General VP | Profile | |
| Kenneth Reali | CEO Director | Profile | |
| MBA BS | Senior Operations | Profile | |
| Helen Leupold | Senior Officer | Profile | |
| Katrina Church | VP Officer | Profile | |
| Alessandraa Pavesio | VP Officer | Profile |
Additional Tools for Bioventus Stock Analysis
When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.